{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:45:27Z","timestamp":1786985127300,"version":"build-2736575974"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,6]],"date-time":"2017-04-06T00:00:00Z","timestamp":1491436800000},"content-version":"am","delay-in-days":340,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Louisiana Cancer Research Consortium (LCRC)"},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"publisher","award":["PC0810811"],"award-info":[{"award-number":["PC0810811"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimie"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.biochi.2016.01.014","type":"journal-article","created":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T05:09:54Z","timestamp":1454303394000},"page":"53-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7\/Dox breast cancer cells"],"prefix":"10.1016","volume":"124","author":[{"given":"Geetika","family":"Chakravarty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi","family":"Mallade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Gerlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joniece","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Datta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudesh","family":"Srivastav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim B.","family":"Abdel-Mageed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasis","family":"Mondal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biochi.2016.01.014_bib1","series-title":"SEER Cancer Statistics Review 1975-2007","year":"2010"},{"issue":"2","key":"10.1016\/j.biochi.2016.01.014_bib2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10147-014-0712-4","article-title":"Aggressive estrogen-receptor-positive breast cancer arising in patients with elevated body mass index","volume":"20","author":"Santa-Maria","year":"2015","journal-title":"Int. J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.biochi.2016.01.014_bib3","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/bjs.9545","article-title":"Surgical treatment of primary breast cancer in the neoadjuvant setting","volume":"101","author":"K\u00fcmmel","year":"2014","journal-title":"Br. J. Surg."},{"issue":"8","key":"10.1016\/j.biochi.2016.01.014_bib4","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1007\/s12094-014-1164-z","article-title":"The use of radiotherapy for early breast cancer in woman at different ages","volume":"16","author":"Calvo","year":"2014","journal-title":"Clin. Transl. Oncol."},{"issue":"4","key":"10.1016\/j.biochi.2016.01.014_bib5","doi-asserted-by":"crossref","first-page":"281","DOI":"10.7150\/jca.8016","article-title":"Current approaches and challenges in early detection of breast cancer recurrence","volume":"5","author":"Schneble","year":"2014","journal-title":"J.\u00a0Cancer"},{"issue":"12","key":"10.1016\/j.biochi.2016.01.014_bib6","first-page":"1210","article-title":"Adjuvant endocrine therapy for breast cancer: how long is long enough?","volume":"27","author":"Jankowitz","year":"2013","journal-title":"Oncology (Williston Park)"},{"issue":"30","key":"10.1016\/j.biochi.2016.01.014_bib7","doi-asserted-by":"crossref","first-page":"4879","DOI":"10.2174\/1381612819666131125145517","article-title":"Breast cancer biomarkers: risk assessment, diagnosis, prognosis, prediction of treatment efficacy and toxicity, and recurrence","volume":"20","author":"M Braden","year":"2014","journal-title":"Curr. Pharm. Des."},{"issue":"6","key":"10.1016\/j.biochi.2016.01.014_bib8","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/annonc\/mdu007","article-title":"Anthracyclines and taxanes in the neo\/adjuvant treatment of breast cancer: does the sequence matter?","volume":"25","author":"Bines","year":"2014","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.biochi.2016.01.014_bib9","doi-asserted-by":"crossref","first-page":"529","DOI":"10.5306\/wjco.v5.i3.529","article-title":"Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines","volume":"5","author":"Crozier","year":"2014","journal-title":"World J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.biochi.2016.01.014_bib10","first-page":"312","article-title":"Deconstructing breast cancer cell biology and the mechanisms of multidrug resistance","volume":"1846","author":"Videira","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"issue":"6","key":"10.1016\/j.biochi.2016.01.014_bib11","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2217\/fon.14.301","article-title":"Recurrence and metastasis of breast cancer is influenced by ovarian hormone's effect on breast cancer stem cells","volume":"11","author":"Nandy","year":"2015","journal-title":"Future Oncol."},{"issue":"5","key":"10.1016\/j.biochi.2016.01.014_bib12","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2174\/138161282005140214165212","article-title":"ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development","volume":"20","author":"Choi","year":"2014","journal-title":"Curr. Pharm. Des."},{"issue":"8","key":"10.1016\/j.biochi.2016.01.014_bib13","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.biotechadv.2013.06.004","article-title":"Different strategies to overcome multidrug resistance in cancer","volume":"31","author":"Saraswathy","year":"2013","journal-title":"Biotechnol. Adv."},{"issue":"6","key":"10.1016\/j.biochi.2016.01.014_bib14","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.drup.2006.11.001","article-title":"The proteasome as a potential target for novel anticancer drugs and chemosensitizers","volume":"9","author":"Landis-Piwowar","year":"2006","journal-title":"Drug Resist Updat"},{"issue":"5","key":"10.1016\/j.biochi.2016.01.014_bib15","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1517\/17425255.2011.562892","article-title":"Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?","volume":"7","author":"Br\u00f3zik","year":"2011","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"1","key":"10.1016\/j.biochi.2016.01.014_bib16","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"10.1016\/j.biochi.2016.01.014_bib17","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1248\/bpb.32.2002","article-title":"Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir","volume":"32","author":"Roy","year":"2009","journal-title":"Biol. Pharm. Bull."},{"issue":"2","key":"10.1016\/j.biochi.2016.01.014_bib18","first-page":"389","article-title":"Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in\u00a0vitro resistance to taxol and doxorubicin","volume":"4","author":"Mechetner","year":"1998","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.biochi.2016.01.014_bib19","first-page":"287","article-title":"Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer","volume":"35","author":"Kovalev","year":"2013","journal-title":"Exp. Oncol."},{"issue":"2","key":"10.1016\/j.biochi.2016.01.014_bib20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1586\/era.12.173","article-title":"Overcoming endocrine resistance in breast cancer: role of the PI3K and the mTOR pathways","volume":"13","author":"Provenzano","year":"2013","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.biochi.2016.01.014_bib21","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jbior.2014.09.016","article-title":"Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis","volume":"57","author":"McCubrey","year":"2015","journal-title":"Adv. Biol. Regul."},{"issue":"11","key":"10.1016\/j.biochi.2016.01.014_bib22","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.4158\/EP14208.RA","article-title":"Insulin-like growth factors, insulin, and growth hormone signaling in breast cancer: implications for targeted therapy","volume":"20","author":"Beckwith","year":"2014","journal-title":"Endocr. Pract."},{"issue":"6","key":"10.1016\/j.biochi.2016.01.014_bib23","doi-asserted-by":"crossref","first-page":"670","DOI":"10.6004\/jnccn.2013.0086","article-title":"The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer","volume":"11","author":"Lauring","year":"2013","journal-title":"J.\u00a0Natl. Compr. Canc Netw."},{"issue":"48","key":"10.1016\/j.biochi.2016.01.014_bib24","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1126\/scitranslmed.3000630","article-title":"Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer","volume":"2","author":"Wallin","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biochi.2016.01.014_bib25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.12703\/P7-13","article-title":"The phosphoinositide 3-kinase pathway and therapy resistance in cancer","volume":"7","author":"Brown","year":"2015","journal-title":"F1000Prime Rep."},{"issue":"21","key":"10.1016\/j.biochi.2016.01.014_bib26","doi-asserted-by":"crossref","first-page":"20310","DOI":"10.1074\/jbc.M500737200","article-title":"Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2","volume":"280","author":"Misra","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"issue":"2","key":"10.1016\/j.biochi.2016.01.014_bib27","first-page":"426","article-title":"Signal transduction pathways and transcriptional mechanisms of ABCB1\/Pgp-mediated multiple drug resistance in human cancer cells","volume":"40","author":"Sui","year":"2012","journal-title":"J.\u00a0Int. Med. Res."},{"issue":"3","key":"10.1016\/j.biochi.2016.01.014_bib28","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1124\/jpet.112.199802","article-title":"Autophagy inhibition for chemosensitization and radiosensitization in cancer: do the preclinical data support this therapeutic strategy?","volume":"344","author":"Bristol","year":"2013","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biochi.2016.01.014_bib29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.semcancer.2015.03.003","article-title":"Controlling the unfolded protein response-mediated life and death decisions in cancer","volume":"33","author":"Maurel","year":"2015","journal-title":"Semin. Cancer Biol."},{"issue":"2","key":"10.1016\/j.biochi.2016.01.014_bib30","doi-asserted-by":"crossref","first-page":"75","DOI":"10.15430\/JCP.2014.19.2.75","article-title":"Endoplasmic reticulum stress and cancer","volume":"19","author":"Yadav","year":"2014","journal-title":"J.\u00a0Cancer Prev."},{"issue":"2","key":"10.1016\/j.biochi.2016.01.014_bib31","first-page":"277","article-title":"The unfolded protein response as a target for cancer therapy","volume":"1846","author":"Nagelkerke","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"issue":"8","key":"10.1016\/j.biochi.2016.01.014_bib32","doi-asserted-by":"crossref","first-page":"e103109","DOI":"10.1371\/journal.pone.0103109","article-title":"Subverting ER-stress towards apoptosis by nelfinavir and curcumin coexposure augments docetaxel efficacy in castration resistant prostate cancer cells","volume":"9","author":"Mathur","year":"2014","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.biochi.2016.01.014_bib33","doi-asserted-by":"crossref","first-page":"17154","DOI":"10.3390\/molecules191117154","article-title":"Enhancing the delivery of resveratrol in humans: if low bioavailability is the problem, what is the solution?","volume":"19","author":"Smoliga","year":"2014","journal-title":"Molecules"},{"issue":"8","key":"10.1016\/j.biochi.2016.01.014_bib34","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biochi.2016.01.014_bib35","series-title":"Roundtable on Translating Genomic-based Research for Health, Board on Health Sciences Policy, Institute of Medicine. Drug Repurposing and Repositioning: Workshop Summary","year":"2014"},{"issue":"17","key":"10.1016\/j.biochi.2016.01.014_bib36","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1158\/1078-0432.CCR-07-0161","article-title":"Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in\u00a0vitro and in\u00a0vivo","volume":"13","author":"Gills","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.biochi.2016.01.014_bib37","doi-asserted-by":"crossref","first-page":"654","DOI":"10.7150\/ijbs.9224","article-title":"Recent advances in drug repositioning for the discovery of new anticancer drugs","volume":"10","author":"Shim","year":"2014","journal-title":"Int. J. Biol. Sci."},{"issue":"18","key":"10.1016\/j.biochi.2016.01.014_bib38","doi-asserted-by":"crossref","first-page":"8161","DOI":"10.18632\/oncotarget.2415","article-title":"A\u00a0phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors","volume":"5","author":"Blumenthal","year":"2014","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.biochi.2016.01.014_bib39","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.bcp.2007.01.027","article-title":"Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein","volume":"73","author":"Storch","year":"2007","journal-title":"Biochem. Pharmacol."},{"issue":"9","key":"10.1016\/j.biochi.2016.01.014_bib40","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1158\/0008-5472.CAN-03-2033","article-title":"Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier","volume":"64","author":"Cisternino","year":"2004","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.biochi.2016.01.014_bib41","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/jnr.21898","article-title":"Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line","volume":"87","author":"Zastre","year":"2009","journal-title":"J.\u00a0Neurosci. Res."},{"issue":"5","key":"10.1016\/j.biochi.2016.01.014_bib42","first-page":"913","article-title":"Human breast cancer MCF-7 cell line contains inherently drug-resistant subclones with distinct genotypic and phenotypic features","volume":"20","author":"Devarajan","year":"2002","journal-title":"Int. J. Oncol."},{"issue":"1","key":"10.1016\/j.biochi.2016.01.014_bib43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.canlet.2015.03.009","article-title":"Selective targeting of FAK-Pyk2 axis by alpha-naphthoflavone abrogates doxorubicin resistance in breast cancer cells","volume":"362","author":"Datta","year":"2015","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.biochi.2016.01.014_bib44","doi-asserted-by":"crossref","first-page":"e75374","DOI":"10.1371\/journal.pone.0075374","article-title":"Specific increase in MDR1 mediated drug-efflux in human brain endothelial cells following co-exposure to HIV-1 and saquinavir","volume":"8","author":"Roy","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.biochi.2016.01.014_bib45","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1038\/cdd.2012.74","article-title":"PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROS-based ER stress","volume":"19","author":"Verfaillie","year":"2012","journal-title":"Cell Death Differ."},{"issue":"3","key":"10.1016\/j.biochi.2016.01.014_bib46","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.radonc.2013.06.005","article-title":"New small molecule inhibitors of UPR activation demonstrate that PERK, but not IRE1\u03b1 signaling is essential for promoting adaptation and survival to hypoxia","volume":"108","author":"Cojocari","year":"2013","journal-title":"Radiother. Oncol."},{"issue":"6","key":"10.1016\/j.biochi.2016.01.014_bib47","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.molonc.2013.07.010","article-title":"Nelfinavir and bortezomib inhibit mTOR activity via ATF4-mediated sestrin-2 regulation","volume":"7","author":"Br\u00fcning","year":"2013","journal-title":"Mol. Oncol."},{"issue":"7","key":"10.1016\/j.biochi.2016.01.014_bib48","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.4161\/auto.5.7.9508","article-title":"TRB3 links ER stress to autophagy in cannabinoid anti-tumoral action","volume":"5","author":"Salazar","year":"2009","journal-title":"Autophagy"},{"issue":"10","key":"10.1016\/j.biochi.2016.01.014_bib49","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.4161\/cbt.4.10.2205","article-title":"Genotoxic and endoplasmic reticulum stresses differentially regulate TRB3 expression","volume":"4","author":"Corcoran","year":"2005","journal-title":"Cancer Biol. Ther."},{"issue":"12","key":"10.1016\/j.biochi.2016.01.014_bib50","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/cdd.2013.128","article-title":"A\u00a0feed-forward loop involving Trib3, Akt and FoxO mediates death of NGF-deprived neurons","volume":"20","author":"Zareen","year":"2013","journal-title":"Cell Death Differ."},{"issue":"3","key":"10.1016\/j.biochi.2016.01.014_bib51","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1677\/JOE-08-0331","article-title":"TRIB3 is implicated in glucotoxicity- and endoplasmic reticulum-stress-induced beta-cell apoptosis","volume":"199","author":"Qian","year":"2008","journal-title":"J.\u00a0Endocrinol."},{"issue":"8","key":"10.1016\/j.biochi.2016.01.014_bib52","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","article-title":"Roles of the Raf\/MEK\/ERK pathway in cell growth, malignant transformation and drug resistance","volume":"1773","author":"McCubrey","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"issue":"9","key":"10.1016\/j.biochi.2016.01.014_bib53","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.4161\/auto.7.9.16521","article-title":"Autophagy protects breast cancer cells from epirubicin-induced apoptosis and facilitates epirubicin-resistance development","volume":"7","author":"Sun","year":"2011","journal-title":"Autophagy"},{"issue":"5","key":"10.1016\/j.biochi.2016.01.014_bib54","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.tcb.2012.02.006","article-title":"Bidirectional crosstalk between endoplasmic reticulum stress and mTOR signaling","volume":"22","author":"Appenzeller-Herzog","year":"2012","journal-title":"Trends Cell Biol."},{"issue":"14","key":"10.1016\/j.biochi.2016.01.014_bib55","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.4161\/cbt.22251","article-title":"Protective effects of alanyl-glutamine supplementation against nelfinavir-induced epithelial impairment in IEC-6 cells and in mouse intestinal mucosa","volume":"13","author":"Braga-Neto","year":"2012","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.biochi.2016.01.014_bib56","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1038\/cddis.2012.87","article-title":"Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells","volume":"3","author":"Kawabata","year":"2012","journal-title":"Cell Death Dis."},{"issue":"16","key":"10.1016\/j.biochi.2016.01.014_bib57","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1093\/jnci\/djn240","article-title":"Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer","volume":"100","author":"Ottewell","year":"2008","journal-title":"J.\u00a0Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.biochi.2016.01.014_bib58","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jcp.20014","article-title":"Drug-resistant breast carcinoma (MCF-7) cells are paradoxically sensitive to apoptosis","volume":"200","author":"Chen","year":"2004","journal-title":"J.\u00a0Cell. Physiol."},{"issue":"2","key":"10.1016\/j.biochi.2016.01.014_bib59","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.3390\/cancers3022106","article-title":"Cancer stem cells and side population cells in breast cancer and metastasis","volume":"3","author":"Britton","year":"2011","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.biochi.2016.01.014_bib60","doi-asserted-by":"crossref","first-page":"248","DOI":"10.4149\/neo_2012_032","article-title":"Perifosine downregulates MDR1 gene expression and reverses multidrug-resistant phenotype by inhibiting PI3K\/Akt\/NF-\u03baB signaling pathway in a human breast cancer cell line","volume":"59","author":"Lin","year":"2012","journal-title":"Neoplasma"},{"key":"10.1016\/j.biochi.2016.01.014_bib61","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.6153.1","article-title":"Nelfinavir and other protease inhibitors in cancer: mechanisms involved in anticancer activity. Version 2","author":"Koltai","year":"2015","journal-title":"F1000Res"},{"key":"10.1016\/j.biochi.2016.01.014_bib62","doi-asserted-by":"crossref","first-page":"9698","DOI":"10.1038\/srep09698","article-title":"Nelfinavir and nelfinavir analogs block site-2 protease cleavage to inhibit castration-resistant prostate cancer","volume":"5","author":"Guan","year":"2015","journal-title":"Sci. Rep."},{"issue":"20","key":"10.1016\/j.biochi.2016.01.014_bib63","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1093\/jnci\/djs396","article-title":"Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir","volume":"104","author":"Shim","year":"2012","journal-title":"J.\u00a0Natl. Cancer Inst."}],"container-title":["Biochimie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300908416000420?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300908416000420?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T19:41:51Z","timestamp":1689795711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300908416000420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":63,"alternative-id":["S0300908416000420"],"URL":"https:\/\/doi.org\/10.1016\/j.biochi.2016.01.014","relation":{},"ISSN":["0300-9084"],"issn-type":[{"value":"0300-9084","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7\/Dox breast cancer cells","name":"articletitle","label":"Article Title"},{"value":"Biochimie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biochi.2016.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier B.V. and Soci\u00e9t\u00e9 Fran\u00e7aise de Biochimie et Biologie Mol\u00e9culaire (SFBBM). All rights reserved.","name":"copyright","label":"Copyright"}]}}